Study Identifies Existing Drugs with Potential Longevity Benefits

A new study published in Nature Aging on June 26, 2026, has identified existing drugs that could potentially influence aging processes. Conducted by a team from Northeastern University, the research mapped 1,250 aging-related genes onto the human protein interactome to identify gene clusters corresponding to biological hallmarks of aging.
The researchers assessed 6,442 clinically approved or experimental compounds to evaluate their proximity to these hallmark modules. This approach identified 370 drugs that may affect at least one hallmark of aging, with 14 showing potential pro-longevity effects and another 14 appearing age-accelerating.
Aspirin and oxymetazoline were highlighted as candidates that could beneficially influence specific aging pathways, such as cell-cell communication and nutrient-sensing hallmarks. However, the study does not claim these drugs extend human lifespan, emphasizing the need for further validation in laboratory settings.
Supporting studies have also pointed to the anti-aging potential of drugs like fenofibrate, which has shown to delay aging in mouse models by targeting specific biological pathways.